Dengue vaccines: progress and challenges.
暂无分享,去创建一个
[1] Gregory D. Gromowski,et al. Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. , 2010, Virology.
[2] B. Murphy,et al. rDEN2/4Δ30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults , 2006, Human vaccines.
[3] Rosanna W. Peeling,et al. Dengue: a continuing global threat , 2010, Nature Reviews Microbiology.
[4] S. Halstead. Dengue in the Americas and Southeast Asia: do they differ? , 2006, Revista panamericana de salud publica = Pan American journal of public health.
[5] Tao Dong,et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.
[6] A. Nisalak,et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. , 2008, The American journal of tropical medicine and hygiene.
[7] Brian R. Murphy,et al. Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys , 2005, Journal of Virology.
[8] Prida Malasit,et al. Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010, Science.
[9] B. Murphy,et al. Development of a live attenuated dengue virus vaccine using reverse genetics. , 2006, Viral immunology.
[10] J. Lang. Recent progress on sanofi pasteur's dengue vaccine candidate. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[11] S. Halstead. Antibodies Determine Virulence in Dengue , 2009, Annals of the New York Academy of Sciences.
[12] D. Vaughn,et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults , 2009, Human vaccines.
[13] M. Guzmán,et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. , 2010, The American journal of tropical medicine and hygiene.
[14] S. Halstead,et al. Dengue , 1872, The Lancet.
[15] A. Rothman. T Lymphocyte Responses to Heterologous Secondary Dengue Virus Infections , 2009, Annals of the New York Academy of Sciences.
[16] A. Fauci,et al. Dengue and hemorrhagic fever: a potential threat to public health in the United States. , 2008, JAMA.
[17] B. Guy,et al. Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). , 2006, Vaccine.
[18] S. Halstead,et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. , 2001, The American journal of tropical medicine and hygiene.
[19] A. Nisalak,et al. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. , 2005, The Journal of infectious diseases.
[20] Gregory D. Gromowski,et al. Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes , 2007, Journal of Virology.
[21] D. Gubler. The global emergence/resurgence of arboviral diseases as public health problems. , 2002, Archives of medical research.
[22] T. Scott,et al. Consequences of the Expanding Global Distribution of Aedes albopictus for Dengue Virus Transmission , 2010, PLoS neglected tropical diseases.
[23] C. Nelson,et al. The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 , 2010, PLoS pathogens.
[24] B. Guy,et al. Development of sanofi pasteur tetravalent dengue vaccine , 2010, Human vaccines.
[25] Cameron P Simmons,et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. , 2010, Cell host & microbe.
[26] M. Guzmán,et al. The epidemiology of dengue in the americas over the last three decades: a worrisome reality. , 2010, The American journal of tropical medicine and hygiene.
[27] R. Jarman,et al. A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model , 2009, PLoS medicine.
[28] G. Perng,et al. A Re‐evaluation of the Mechanisms Leading to Dengue Hemorrhagic Fever , 2009, Annals of the New York Academy of Sciences.
[29] B. Murphy,et al. The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers , 2006, Human vaccines.
[30] B. McKinney,et al. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. , 2009, The American journal of tropical medicine and hygiene.
[31] F. Guirakhoo,et al. Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.
[32] J. Mendez-Galvan,et al. The growing burden of dengue in Latin America. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[33] A. Rothman,et al. Understanding the contribution of cellular immunity to dengue disease pathogenesis , 2008, Immunological reviews.
[34] M. Accavitti-Loper,et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.
[35] A. Nisalak,et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. , 2006, The Journal of infectious diseases.
[36] J. Smit,et al. Immature Dengue Virus: A Veiled Pathogen? , 2010, PLoS pathogens.
[37] Immunogenicity of sanofi pasteur tetravalent dengue vaccine. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[38] Soila Sukupolvi-Petty,et al. Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3 , 2010, Journal of Virology.
[39] Aidan McDermott,et al. The Impact of the Demographic Transition on Dengue in Thailand: Insights from a Statistical Analysis and Mathematical Modeling , 2009, PLoS medicine.
[40] N. Lennon,et al. Emergence of the Asian 1 Genotype of Dengue Virus Serotype 2 in Viet Nam: In Vivo Fitness Advantage and Lineage Replacement in South-East Asia , 2010, PLoS neglected tropical diseases.
[41] C. Huang,et al. Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development , 2003, Journal of Virology.
[42] D. Gubler,et al. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. , 2009, Cadernos de saude publica.
[43] Alfonso Gúzman,et al. Update on the global spread of dengue. , 2010, International journal of antimicrobial agents.
[44] B. Guy,et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. , 2010, Vaccine.
[45] A. Nisalak,et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study , 2007, The Lancet.
[46] S. Halstead,et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. , 2009, The American journal of tropical medicine and hygiene.
[47] B. Murphy,et al. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. , 2008, The American journal of tropical medicine and hygiene.
[48] A. Nisalak,et al. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. , 2005, The American journal of tropical medicine and hygiene.
[49] B. Murphy,et al. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1 , 2007, Virology Journal.
[50] A. Nisalak,et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. , 2008, The American journal of tropical medicine and hygiene.
[51] A. Nisalak,et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. , 2002, The Journal of infectious diseases.
[52] M. Diamond,et al. Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification , 2010, PLoS pathogens.
[53] Ralph S. Baric,et al. Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses , 2010, PLoS pathogens.
[54] J. Smit,et al. Functional importance of dengue virus maturation: infectious properties of immature virions. , 2008, The Journal of general virology.
[55] J. Lang,et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. , 2010, The Journal of infectious diseases.
[56] C. Stratton,et al. Sensitive, qualitative detection of human herpesvirus-6 and simultaneous differentiation of variants A and B. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[57] K. Porter,et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. , 2011, Vaccine.
[58] B. Guy,et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. , 2008, Vaccine.
[59] G. Chang,et al. Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II , 2008, Journal of Virology.
[60] J. Lang,et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. , 2006, Vaccine.
[61] Steven A. Ogata,et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. , 2010, Vaccine.
[62] Mario Recker,et al. Immunological serotype interactions and their effect on the epidemiological pattern of dengue , 2009, Proceedings of the Royal Society B: Biological Sciences.
[63] J. Farrar,et al. Changing Patterns of Dengue Epidemiology and Implications for Clinical Management and Vaccines , 2009, PLoS medicine.
[64] A. Rothman,et al. Dengue immune response: low affinity, high febrility , 2003, Nature Medicine.
[65] Derek A. T. Cummings,et al. Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006 , 2010, PLoS neglected tropical diseases.